ProfileGDS4814 / ILMN_1736142
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 21% 11% 10% 51% 32% 22% 3% 8% 6% 23% 33% 5% 15% 20% 3% 18% 49% 1% 7% 29% 1% 12% 20% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)43.80221
GSM780708Untreated after 4 days (C2_1)41.468511
GSM780709Untreated after 4 days (C3_1)41.10610
GSM780719Untreated after 4 days (C1_2)50.855551
GSM780720Untreated after 4 days (C2_2)45.938732
GSM780721Untreated after 4 days (C3_2)44.009522
GSM780710Trastuzumab treated after 4 days (T1_1)38.31393
GSM780711Trastuzumab treated after 4 days (T2_1)40.66178
GSM780712Trastuzumab treated after 4 days (T3_1)39.89976
GSM780722Trastuzumab treated after 4 days (T1_2)44.277523
GSM780723Trastuzumab treated after 4 days (T2_2)46.133433
GSM780724Trastuzumab treated after 4 days (T3_2)39.6065
GSM780713Pertuzumab treated after 4 days (P1_1)42.564615
GSM780714Pertuzumab treated after 4 days (P2_1)43.536720
GSM780715Pertuzumab treated after 4 days (P3_1)38.59883
GSM780725Pertuzumab treated after 4 days (P1_2)43.039818
GSM780726Pertuzumab treated after 4 days (P2_2)50.014249
GSM780727Pertuzumab treated after 4 days (P3_2)34.20861
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)40.36367
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)45.414229
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)34.95631
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)41.838312
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)43.476320